Klinik für Hals-Nasen-Ohrenheilkunde, Universitätsklinikum Düsseldorf, Düsseldorf, Germany.
Medizinische Klinik 2, Universitätsklinikum Frankfurt, Frankfurt am Main, Germany.
Clin Appl Thromb Hemost. 2023 Jan-Dec;29:10760296231152898. doi: 10.1177/10760296231152898.
Deep vein thrombosis (DVT) and the associated possible complication of pulmonary artery embolism (LAE) represent a recognized reason for significant perioperative morbidity and mortality. There is a risk of pulmonary artery embolism through embolization. The aim of the study was to investigate the influence of various risk factors on the clinical outcome of the therapy, particularly regarding whether maintenance therapy offers a benefit in terms of the frequency of bleeding and thrombotic events. 80 patients were included, some of them retrospectively from July 2018. The observational period was set to 12 months after the DVT event. In the present sample with n = 80, with 57.5% men and 42.5% women (after 12 months of observation: n = 78), a success rate of the therapies administered of 89.7% was recorded. Only 8.9% showed partial recanalization. 3.8% of the patients had a relapse (also beyond the localization of the leg and pelvic veins) and 8.8% had a residual thrombus during the first 12 months of observation. In this study, BARC (leeding cademic esearch onsortium) and HAS-BLED (ypertension, bnormal renal and liver function, troke, leeding, abile INR, lderly, rugs or alcohol) scores for identifying the risk of bleeding and Wells scores for assessing the risk of having a thrombosis were used. The Villalta score tested in this study showed significant correlations with residual thrombus ( < .001), recurrence within 12 months ( < .001), and the risk of bleeding ( < .001) and is capable to provide an assessment of the variables mentioned not only at the possible end of therapy but also at the start of anticoagulant therapy.
深静脉血栓形成(DVT)和与之相关的肺动脉栓塞(PE)并发症是导致围手术期发病率和死亡率显著增加的公认原因。存在通过栓塞导致肺动脉栓塞的风险。该研究的目的是调查各种危险因素对治疗临床结果的影响,特别是维持治疗在出血和血栓事件的频率方面是否具有益处。纳入了 80 名患者,其中一些是回顾性纳入的,来自 2018 年 7 月。观察期设定为 DVT 事件后 12 个月。在本样本中,n=80,男性占 57.5%,女性占 42.5%(观察 12 个月后:n=78),记录到所给予治疗的成功率为 89.7%。只有 8.9%显示部分再通。3.8%的患者复发(也超过腿部和盆腔静脉的定位),8.8%的患者在观察的前 12 个月有残留血栓。在这项研究中,使用了 BARC(出血学术研究联合会)和 HAS-BLED(高血压、异常肾功能和肝功能、中风、出血、可变国际标准化比值、老年、药物或酒精)评分来识别出血风险,以及 Wells 评分来评估血栓形成的风险。在这项研究中测试的 Villalta 评分与残留血栓( < .001)、12 个月内复发( < .001)以及出血风险( < .001)显著相关,并且能够评估不仅在可能的治疗结束时,而且在抗凝治疗开始时提到的变量。